ANTX
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
AN2 Therapeutics, Inc. (ANTX) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Growth (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | C+ (2.5) | C- (2.0) | B- (2.9) | C (2.3) | C+ (2.6) | C (2.5) |
| 2026-11-10 | C+ (2.5) | C- (2.0) | B- (2.9) | C+ (2.5) | C+ (2.6) | C+ (2.5) |
| 2026-11-03 | C+ (2.5) | C- (2.0) | B- (2.9) | B- (2.9) | C+ (2.7) | C+ (2.6) |
| 2026-10-27 | C+ (2.5) | C- (1.9) | B- (3.0) | C+ (2.6) | C+ (2.6) | C+ (2.5) |
| 2026-10-20 | C+ (2.5) | C- (1.9) | B- (3.0) | B- (3.0) | C+ (2.6) | C+ (2.6) |